Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MD-1100 · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| MD-1100 Acetate | DRUG | - |
Inclusion Criteria: * Male or non-pregnant, non-breastfeeding female, age 18-70 years old at the time of first dose; * Sexually active patients of childbearing potential agree to use double-barrier birth control; * Females of childbearing potential must complete negative pregnancy tests prior to fi...
MD-1100 is an investigational small molecule being developed by Ironwood Pharmaceuticals for the treatment of constipation and irritable bowel syndrome. It is currently in Phase 2 clinical development, with completed trials in patients with chronic constipation and constipation-predominant irritable bowel syndrome.
MD-1100 is being developed by Ironwood Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol IRWD. The company is conducting clinical trials of MD-1100 for gastrointestinal conditions.
MD-1100 is in Phase 2 clinical development. Two Phase 2 trials have been completed, one in patients with irritable bowel syndrome and one in patients with chronic constipation. The drug is investigational and has not been approved by regulatory authorities.
MD-1100 has been studied in two completed Phase 2 trials. NCT00258193 evaluated MD-1100 acetate on gastrointestinal transit in patients with irritable bowel syndrome, enrolling 36 participants. NCT00306748 evaluated MD-1100 acetate administered for 14 days in patients with chronic constipation, enrolling 40 participants.
Yes, MD-1100 acetate is the salt form of MD-1100. The clinical trials NCT00258193 and NCT00306748 both studied MD-1100 acetate, which is the active pharmaceutical ingredient in the investigational drug product.